Skip to main content
Top
Published in: Clinical Research in Cardiology 1/2015

01-01-2015 | Original Paper

Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study

Authors: V. Simopoulos, G. Tagarakis, A. Hatziefthimiou, I. Skoularigis, F. Triposkiadis, V. Trantou, N. Tsilimingas, I. Aidonidis

Published in: Clinical Research in Cardiology | Issue 1/2015

Login to get access

Abstract

Postoperative atrial fibrillation (POAF) is the most common arrhythmia after cardiac surgery. There exist consistent experimental and clinical data suggesting that aldosterone antagonists (AAs) may exert beneficial effects regarding electrical and structural remodeling in failing myocardium. Recently, eplerenone (EPL) has been found to reduce the incidence of nonsurgical AF when added to guideline-recommended therapy in patients with systolic heart failure. Based on these findings, we primarily aimed to evaluate by retrospective analysis the impact of the two AAs, EPL and spironolactone (SPL), given at standard therapeutic doses in preventing new-onset POAF in patients the majority of which had a preoperative ejection fraction (EF) below 40 %. A total of 332 patients (298 men/34 women, mean age 64.3 ± 9 years) without history of AF were included in this analysis; 132 of these patients received long-term EPL or SPL in addition to beta-blockade/statins therapy and 200 patients received neither EPL nor SPL. All patients underwent on-pump coronary artery bypass graft (80 %) and/or valvular surgery (20 %). In the nonAA group (EF = 35.8 ± 6 %) 90/200 patients (45 %) had POAF, while in the AA group (EF = 36.2 ± 5 %) only 40/132 patients (30.3 %) developed POAF (P < 0.01, χ 2 test). Multivariate logistic regression analysis revealed that only AAs and left atrial diameter significantly affected the development of POAF even when adjusted for other clinical variables (P < 0.05). In conclusion, AAs significantly reduced the incidence of POAF when added to standard heart failure therapy in patients undergoing on-pump cardiac surgery.
Literature
1.
go back to reference Hogue CW, Hyder ML (2000) Atrial fibrillation after cardiac operation: risks, mechanisms, and treatment. Ann Thorac Surg 69:300–306PubMedCrossRef Hogue CW, Hyder ML (2000) Atrial fibrillation after cardiac operation: risks, mechanisms, and treatment. Ann Thorac Surg 69:300–306PubMedCrossRef
2.
go back to reference Cao L, Li Q, Bi Q, Yu QJ (2011) Risk factors for recurrent stroke after coronary artery bypass grafting. J Cardiothorac Surg 23(6):157CrossRef Cao L, Li Q, Bi Q, Yu QJ (2011) Risk factors for recurrent stroke after coronary artery bypass grafting. J Cardiothorac Surg 23(6):157CrossRef
3.
go back to reference Aidonidis I, Doulas K, Hatziefthimiou A et al (2013) Ranolazine-induced postrepolarization refractoriness suppresses induction of atrial flutter and fibrillation in anesthetized rabbits. J Cardiovasc Pharmacol Ther 18(1):94–101PubMedCrossRef Aidonidis I, Doulas K, Hatziefthimiou A et al (2013) Ranolazine-induced postrepolarization refractoriness suppresses induction of atrial flutter and fibrillation in anesthetized rabbits. J Cardiovasc Pharmacol Ther 18(1):94–101PubMedCrossRef
4.
go back to reference Tagarakis GI, Aidonidis I, Daskalopoulou SS et al (2014) Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery. Curr Vasc Pharmacol 11(6):988–991CrossRef Tagarakis GI, Aidonidis I, Daskalopoulou SS et al (2014) Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery. Curr Vasc Pharmacol 11(6):988–991CrossRef
5.
go back to reference Swedberg K, Zannag F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H (2012) Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in mild patients hospitalization and survival study in heart failure) study. Am Coll Cardiol 59(18):1598–1603CrossRef Swedberg K, Zannag F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H (2012) Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in mild patients hospitalization and survival study in heart failure) study. Am Coll Cardiol 59(18):1598–1603CrossRef
6.
go back to reference Lendeckel U, Dobrev D, Goette A (2010) Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation. Br J Pharmacol 159(8):1581–1583PubMedCentralPubMedCrossRef Lendeckel U, Dobrev D, Goette A (2010) Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation. Br J Pharmacol 159(8):1581–1583PubMedCentralPubMedCrossRef
7.
go back to reference Lammers C, Dartsch T, Brandt MC, Rottlander D, Halbach M, Peinkofer G et al (2012) Spironolactone prevents aldosterone induced increased duration of fibrillation in rat. Cell Physiol Biochem 29(5–6):833–840PubMedCrossRef Lammers C, Dartsch T, Brandt MC, Rottlander D, Halbach M, Peinkofer G et al (2012) Spironolactone prevents aldosterone induced increased duration of fibrillation in rat. Cell Physiol Biochem 29(5–6):833–840PubMedCrossRef
8.
go back to reference Dabrowski R, Szwed H (2012) Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation. Cardiol J 19(3):223–229PubMedCrossRef Dabrowski R, Szwed H (2012) Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation. Cardiol J 19(3):223–229PubMedCrossRef
9.
go back to reference Shroff SC, Ryu K, Martovitz NL et al (2006) Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol 17(5):534–541PubMedCrossRef Shroff SC, Ryu K, Martovitz NL et al (2006) Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol 17(5):534–541PubMedCrossRef
11.
go back to reference Reil JC, Hohl M, Selejan S et al (2012) Aldosterone promotes atrial fibrillation. Eur Heart J 33(16):2098–2108PubMedCrossRef Reil JC, Hohl M, Selejan S et al (2012) Aldosterone promotes atrial fibrillation. Eur Heart J 33(16):2098–2108PubMedCrossRef
12.
go back to reference Milliez P, Deangelis N, Rucker-Martin C et al (2005) Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 26(20):2193–2199PubMedCrossRef Milliez P, Deangelis N, Rucker-Martin C et al (2005) Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 26(20):2193–2199PubMedCrossRef
13.
go back to reference Caballero R, Moreno I, Gonzalez T et al (2003) Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels. Circulation 107:889–895PubMedCrossRef Caballero R, Moreno I, Gonzalez T et al (2003) Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels. Circulation 107:889–895PubMedCrossRef
14.
go back to reference Workman AJ, Pau D, Redpath CJ et al (2009) Atrial cellular electrohysiological changes in patients with ventricular dysfunction may predispose to AF. Heart Rhythm 6:445–451PubMedCentralPubMedCrossRef Workman AJ, Pau D, Redpath CJ et al (2009) Atrial cellular electrohysiological changes in patients with ventricular dysfunction may predispose to AF. Heart Rhythm 6:445–451PubMedCentralPubMedCrossRef
15.
go back to reference Workman AJ, Kane KA, Russell JA et al (2003) Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evdence of pharmacological remodelling. Cardiovasc Res 58:518–525PubMedCrossRef Workman AJ, Kane KA, Russell JA et al (2003) Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evdence of pharmacological remodelling. Cardiovasc Res 58:518–525PubMedCrossRef
16.
go back to reference Mihailidou AS, Bundgaard H, Mardini M et al (2000) Hyperaldosteronemia in rabbits inhibits the cardiac sarcolemmal Na+-K+ pump. Circulation Res 86:37–42PubMedCrossRef Mihailidou AS, Bundgaard H, Mardini M et al (2000) Hyperaldosteronemia in rabbits inhibits the cardiac sarcolemmal Na+-K+ pump. Circulation Res 86:37–42PubMedCrossRef
17.
go back to reference Lavall D, Selzer C, Schuster P et al (2014) The mineralcorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem 289:6656–6668PubMed Lavall D, Selzer C, Schuster P et al (2014) The mineralcorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem 289:6656–6668PubMed
18.
go back to reference Neuberger HR, Schotten U, Verheule S et al (2005) Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat. Circulation 111:30–37PubMedCrossRef Neuberger HR, Schotten U, Verheule S et al (2005) Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat. Circulation 111:30–37PubMedCrossRef
19.
go back to reference Tsai CT, Chiang FT, Tseng CD et al (2010) Increased expression of mineralcorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol 55(8):758–770PubMedCrossRef Tsai CT, Chiang FT, Tseng CD et al (2010) Increased expression of mineralcorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol 55(8):758–770PubMedCrossRef
20.
go back to reference Lampe B, Hamerstingl C, Schwab JO et al (2012) Adverse effects of permanent atrial fibrillation on heart failure in patients with preserved left ventricular function and chronic right apical pacing for complete heart block. Clin Res Cardiol 101(10):829–836PubMedCrossRef Lampe B, Hamerstingl C, Schwab JO et al (2012) Adverse effects of permanent atrial fibrillation on heart failure in patients with preserved left ventricular function and chronic right apical pacing for complete heart block. Clin Res Cardiol 101(10):829–836PubMedCrossRef
21.
go back to reference Neuberger HR, Cacciatore A, Reil JC et al (2012) Procollagen-propeptides: serum markers for atrial fibrosis? Clin Res Cardiol 101(8):655–661PubMedCrossRef Neuberger HR, Cacciatore A, Reil JC et al (2012) Procollagen-propeptides: serum markers for atrial fibrosis? Clin Res Cardiol 101(8):655–661PubMedCrossRef
22.
go back to reference Providencia R, Barra S, Paiva L (2013) Atrial fibrillation, elevated troponin, ischemic stroke and adverse outcomes: understanding the connection. Clin Res Cardiol 102(10):701–711PubMedCrossRef Providencia R, Barra S, Paiva L (2013) Atrial fibrillation, elevated troponin, ischemic stroke and adverse outcomes: understanding the connection. Clin Res Cardiol 102(10):701–711PubMedCrossRef
23.
go back to reference Gregori M, Tocci G, Marra A, Pignatelli G et al (2013) Inadequate RAAS suppression is associated with excessive left ventricular mass and systo-diastolic dysfunction. Clin Res Cardiol 102(10):725–733PubMedCrossRef Gregori M, Tocci G, Marra A, Pignatelli G et al (2013) Inadequate RAAS suppression is associated with excessive left ventricular mass and systo-diastolic dysfunction. Clin Res Cardiol 102(10):725–733PubMedCrossRef
24.
go back to reference Linz D, van Hunnik A, Ukena C et al (2014) Renal denervation: effects on atrial electrophysiology and arrhythmias. Clin Res Cardiol 115(3):400–409 Linz D, van Hunnik A, Ukena C et al (2014) Renal denervation: effects on atrial electrophysiology and arrhythmias. Clin Res Cardiol 115(3):400–409
Metadata
Title
Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study
Authors
V. Simopoulos
G. Tagarakis
A. Hatziefthimiou
I. Skoularigis
F. Triposkiadis
V. Trantou
N. Tsilimingas
I. Aidonidis
Publication date
01-01-2015
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology / Issue 1/2015
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-014-0754-7

Other articles of this Issue 1/2015

Clinical Research in Cardiology 1/2015 Go to the issue